CAVC Case 23-0092: Heart
CAVCReal U.S. Court of Appeals for Veterans Claims (CAVC) decision · 2022-11-17 · JAQUITH, Judge
This is a decision of the U.S. Court of Appeals for Veterans Claims — the federal court that reviews Board of Veterans' Appeals decisions, one level above the Board. Court decisions can vacate, reverse, or affirm what the Board did.
Official 2026 VA monthly compensation, including the 2.8% COLA increase.
Dependent add-ons start at a 30% rating. Child-only and dependent-parent rates: see the full 2026 pay chart.
2026 base rates, all ratings (veteran alone)
| Rating | Monthly (2026, incl. 2.8% COLA) |
|---|---|
| 10% | $180.42 |
| 20% | $356.66 |
| 30% | $552.47 |
| 40% | $795.84 |
| 50% | $1,132.90 |
| 60% | $1,435.02 |
| 70% | $1,808.45 |
| 80% | $2,102.15 |
| 90% | $2,362.30 |
| 100% | $3,938.58 |
Conditions Claimed
Referral disclosure: VetAid earns a referral fee if you become a paying REE Medical client through this link — it helps keep this site free. REE Medical provides paid medical evidence; it is not a law firm, VSO, or claims agent, and VetAid has not independently verified its services. VSOs and VA-accredited representatives will help you file your claim at no cost, and no one can guarantee a rating increase.
Issues on Appeal
Service ConnectionEffective Date
Why It Was Decided This Way
The Board found that the April 2015 VA medical opinion address[ing]whether the [v]eteran's current endocrine conditions and hypertension were related to his service-connected diabetes was inadequate because it failed to discuss the theory of aggravation or provide a sufficient explanationfor its conclusions.
In addition,the Board noted that an opinion addressing the potential relationship betweenthe veteran's hypertensionand presumedherbicide exposure was warranted given that the National Academies of Sciences,Engineeringand Medicine (NAS),[had recently]upgraded hypertension from its previous classification in the category of 'limited or suggestive'evidence of an association to Agent Orange to the category of 'sufficient'evidence of an association.
Therefore,an exam was ordered to address (a)whether the veteran's hypertension was at least as likely as not related to his active duty service,to include his presumed exposure to herbicide agents,and (b)whether the veteran's hypertension,adrenal gland condition, thyroid condition,and/or pituitary gland condition were at least as likely as not caused or aggravated by his service-connected diabetes.
In assessing the etiology of the veteran's hypertension, the physician provideda negative opinionregardingdirect service connection,includingin-service herbicide exposure,stating that the diagnosis of hypertension was not evident during active service and thus [was]not related to active service including events,injuries,diseases,or exposures during service.
ditions were all manifestations of his autoimmune polyglandular syndrome type II, but the physician did not address whether his polyglandular syndrome is secondary to his service- connected diabetes.
In addition,the Board found that there may be outstanding VA treatment records that could be relevant to his claim for hypertension,warranting remand for that issue as well.
A September 2022 VA opinion completed by a nurse practitioner concluded that there was scant data supporting a nexus between the current diagnosis of autoimmune polyglandular syndrome type II .
November 2022 Board Decision In the November 17,2022,decision now on appeal,the Board denied service connection for pituitary gland and adrenal gland conditions,to include as secondary to diabetes,and service connection for hypertension except as presumptively related to herbicide exposure pursuant to the PACT Act.
Authorities Cited
Denial Type
No Nexus|Duty To Assist|Inadequate Exam
Find Similar Decisions for Your Claim
VetAid's analyzer maps your claim against thousands of real Board of Veterans' Appeals decisions like this one — surfacing the exact case law that supports your arguments.
Run my claim through VetAid →